- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.12.25 | Kane Biotech Inc (2): Kane Biotech 14-million-share private placement | 2 | Stockwatch | ||
| 18.12.25 | Kane Biotech Inc.: Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company | 1 | GlobeNewswire (USA) | ||
| 17.12.25 | Kane Biotech Inc.: Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 10.12.25 | Kane Biotech Inc.: Kane Biotech Receives Health Canada Approval for revyve Antimicrobial Wound Gel Spray | 1 | GlobeNewswire (USA) | ||
| 28.11.25 | Kane Biotech Inc (2): Kane Biotech loses $607,345 in Q3 2025 | 1 | Stockwatch | ||
| KANE BIOTECH Aktie jetzt für 0€ handeln | |||||
| 28.11.25 | Kane Biotech Inc.: Kane Biotech Announces Third Quarter 2025 Financial Results | 668 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announced its third quarter 2025 financial results. Third Quarter... ► Artikel lesen | |
| 27.11.25 | Kane Biotech Inc (2): Kane Biotech arranges $800,000 private placement | 1 | Stockwatch | ||
| 27.11.25 | Kane Biotech Inc.: Kane Biotech Announces New Private Placement Offering | 2 | GlobeNewswire (USA) | ||
| 04.11.25 | Kane Biotech Inc (2): Kane receives clinical, preclinical data for revyve | 3 | Stockwatch | ||
| 17.09.25 | Kane Biotech Inc (2): Kane Biotech completes submission for wound cleanser | 1 | Stockwatch | ||
| 16.09.25 | Kane Biotech Inc.: Kane Biotech Completes U.S. FDA 510(k) Submission for revyve Antimicrobial Wound Cleanser | 229 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech" or the "Company") today announces that it has completed a U.S. Food and Drug Administration ("FDA")... ► Artikel lesen | |
| 11.09.25 | Kane Biotech Inc (2): Kane Biotech enrolls 28 participants for revyve studies | 2 | Stockwatch | ||
| 10.09.25 | Kane Biotech Inc.: Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve Antimicrobial Wound Gel and Spray | 160 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech" or "Kane") today announces that it has enrolled 28 participants in its revyve® Antimicrobial Wound... ► Artikel lesen | |
| 29.08.25 | Kane Biotech reports Q2 results | 1 | Seeking Alpha | ||
| 28.08.25 | Kane Biotech Inc.: Kane Biotech Announces Second Quarter 2025 Financial Results | 141 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announced its second quarter 2025 financial results. Second Quarter... ► Artikel lesen | |
| 30.07.25 | Kane Biotech Inc (2): Kane Biotech presents revyve wound care data | 2 | Stockwatch | ||
| 18.06.25 | Kane Biotech Inc.: Kane Biotech Provides Further Corporate Update | 200 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the "Company", "Kane" or "Kane Biotech") provides updates on its reorganizational phase. The Company has terminated... ► Artikel lesen | |
| 29.05.25 | Kane Biotech Inc.: Kane Biotech Announces First Quarter 2025 Financial Results | 468 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announces its first quarter 2025 financial results. First Quarter... ► Artikel lesen | |
| 05.05.25 | Kane Biotech Inc.: Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company | 196 | GlobeNewswire (Europe) | Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 05, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the "Company"... ► Artikel lesen | |
| 28.04.25 | Kane Biotech Inc.: Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change | 286 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) ("Kane Biotech", "Kane" or the "Company") today announced its fourth quarter and full year 2024 financial... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,595 | 0,00 % | EQS-News: NanoRepro AG: Aufsichtsratsmitglied kündigt Amtsniederlegung an | EQS-News: NanoRepro AG
/ Schlagwort(e): Personalie
NanoRepro AG: Aufsichtsratsmitglied kündigt Amtsniederlegung an
13.01.2026 / 09:45 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 17,990 | +8,64 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| BRAIN BIOTECH | 2,350 | -3,69 % | EQS-News: BRAIN Biotech AG: Geschäftsjahr 2024/25: BRAIN Biotech AG profitiert durch erfolgreiche Monetarisierung von Projekten und starker Kostenkontrolle | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Jahresbericht/Jahresergebnis
Geschäftsjahr 2024/25: BRAIN Biotech AG profitiert durch erfolgreiche Monetarisierung von Projekten und... ► Artikel lesen | |
| AAP IMPLANTATE | 1,600 | 0,00 % | AAP Implantate AG - Stabilität als strategische Zone | ||
| CO.DON | 0,020 | -11,11 % | EQS-PVR: CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: CO.DON AG
CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.01.2026 / 12:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| BIOXXMED | 1,000 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 13.01.2026 | Das Instrument VHM ES0182870214 SACYR S.A. INH. EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 13.01.2026 The instrument VHM ES0182870214 SACYR S.A. INH. EO 1 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| CLINUVEL | 7,175 | +1,41 % | CLINUVEL PHARMACEUTICALS LIMITED: Managing Director Letter to Shareholders | ||
| SANGAMO THERAPEUTICS | 0,376 | +1,73 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| BIO-GATE | 0,845 | +2,42 % | Bio-Gate: EBITDA verbessert | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im ersten Halbjahr des Geschäftsjahres 2025 (per 31.12.) mit 3,44 Mio. Euro einen leicht unter Vorjahr... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,590 | 0,00 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 1,699 | -2,86 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | TREVENA INC - 8-K, Current Report | ||
| EXELIXIS | 37,800 | -1,15 % | Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO |
Das Unternehmen KANE BIOTECH INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KANE BIOTECH INC finden Sie auf Wallstreet Online.